Effect of 18F-Fluciclovine Positron Emission Tomography on the Management of Patients With Recurrence of Prostate Cancer: Results From the FALCON Trial

Published on Jun 1, 2020in International Journal of Radiation Oncology Biology Physics5.859
· DOI :10.1016/J.IJROBP.2020.01.050
Andrew Scarsbrook29
Estimated H-index: 29
(Leeds Teaching Hospitals NHS Trust),
David Bottomley20
Estimated H-index: 20
(Leeds Teaching Hospitals NHS Trust)
+ 15 AuthorsFergus V. Gleeson58
Estimated H-index: 58
(University of Oxford)
Abstract Purpose Early and accurate localisation of lesions in patients with biochemical recurrence (BCR) of prostate cancer may guide salvage therapy decisions. The present study, XXX, aimed to evaluate the impact of 18F-fluciclovine on management of men with BCR of prostate cancer. Methods Men with a first episode of BCR following curative-intent primary therapy were enrolled at 6 UK sites. Patients underwent 18F-fluciclovine PET/CT according to standardised procedures. Clinicians documented management plans before and after scanning, recording changes to treatment modality as ‘major’ and changes within a modality as ‘other’. The primary outcome measure was record of a revised management plan post-scan. Secondary endpoints were evaluation of optimal PSA threshold for detection, salvage treatment outcome assessment based on 18F-fluciclovine-involvement, and safety. Results 18F-Fluciclovine was well tolerated in the 104 scanned patients (median PSA=0.79 ng/mL). Lesions were detected in 58/104 (56%) patients. Detection was broadly proportional to PSA level; ≤1 ng/mL, 1/3 of scans were positive, while 93% scans were positive at PSA >2.0 ng/mL. Sixty-six (64%) patients had a post-scan management change (80% following a positive result). Major changes (43/66; 65%) were: salvage or systemic therapy to watchful waiting (16/66; 24%); salvage therapy to systemic therapy (16/66; 24%); alternative changes to treatment modality (11/66, 17%). The remaining 23/66 (35%) management changes were modifications of the pre-scan plan: most (22/66; 33%) were adjustments to planned brachytherapy/radiotherapy to include a 18F-fluciclovine-guided boost. Where 18F-fluciclovine guided salvage therapy, the PSA response rate was higher than when 18F-fluciclovine was not involved (15/17 [88%] vs 28/39 [72%]). Conclusions 18F-Fluciclovine PET/CT located recurrence in the majority of men with BCR, frequently resulting in major management plan changes. Incorporating 18F-fluciclovine PET/CT into treatment planning may optimise targeting of recurrence sites and avoid futile salvage therapy.
📖 Papers frequently viewed together
5 Citations
35 Citations
42 Citations
#1David E. Neal (University of Oxford)H-Index: 111
#2Chris Metcalfe (UoB: University of Bristol)H-Index: 61
Last. Tracy E RobertsH-Index: 40
view all 282 authors...
Abstract Background The ProtecT trial reported intention-to-treat analysis of men with localised prostate cancer randomly allocated to active monitoring (AM), radical prostatectomy, and external beam radiotherapy. Objective To report outcomes according to treatment received in men in randomised and treatment choice cohorts. Design, setting, and participants This study focuses on secondary care. Men with clinically localised prostate cancer at one of nine UK centres were invited to participate in...
45 CitationsSource
#1Gerald L. Andriole (WashU: Washington University in St. Louis)H-Index: 7
#1Gerald L. Andriole (WashU: Washington University in St. Louis)H-Index: 97
5 CitationsSource
#1Birgit Pernthaler (Medical University of Graz)H-Index: 1
#2Roman KulnikH-Index: 3
Last. Herbert KvaternikH-Index: 6
view all 6 authors...
PurposeOne of the major challenges for all imaging modalities is accurate detection of prostate cancer (PCa) recurrence. Beyond the established 68Ga-PSMA, a novel promising PET tracer in PCa imaging is 18F-fluciclovine. For evaluating the advantages and disadvantages and the comparability, we conduc
38 CitationsSource
#1Jeremie Calais (UCLA: University of California, Los Angeles)H-Index: 20
#2Francesco Ceci (UNITO: University of Turin)H-Index: 24
Last. Johannes Czernin (UCLA: University of California, Los Angeles)H-Index: 94
view all 22 authors...
Summary Background National Comprehensive Cancer Network guidelines consider 18F-fluciclovine PET-CT for prostate cancer biochemical recurrence localisation after radical prostatectomy, whereas European Association of Urology guidelines recommend prostate-specific membrane antigen (PSMA) PET-CT. To the best of our knowledge, no prospective head-to-head comparison between these tests has been done so far. The aim of this study was to compare prospectively paired 18F-fluciclovine and PSMA PET-CT s...
149 CitationsSource
#1Gerald L. Andriole (WashU: Washington University in St. Louis)H-Index: 97
#2Lale Kostakoglu (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 56
Last. Barry A. Siegel (WashU: Washington University in St. Louis)H-Index: 103
view all 8 authors...
Purpose:The prospective, multicenter LOCATE (18F Fluciclovine [FACBC] PET/CT in Patients with Rising PSA after Initial Prostate Cancer Treatment) trial assessed the impact of positron emission tomography/computerized tomography with 18F-fluciclovine on treatment plans in patients with biochemical recurrence of prostate cancer after primary therapy with curative intent.Materials and Methods:Men who had undergone curative intent treatment of histologically confirmed prostate cancer but who were su...
61 CitationsSource
#1Jeremie Calais (UCLA Medical Center)H-Index: 20
#2Wolfgang P. Fendler (UCLA Medical Center)H-Index: 30
Last. Ken Herrmann (UCLA Medical Center)H-Index: 2
view all 17 authors...
In this prospective survey of referring physicians, we investigated whether and how 68Ga-labeled prostate-specific membrane antigen 11 (68Ga-PSMA-11) PET/CT affects the implemented management of prostate cancer patients with biochemical recurrence (BCR). Methods: We conducted a prospective survey of physicians ({"type":"clinical-trial","attrs":{"text":"NCT02940262","term_id":"NCT02940262"}}NCT02940262) who referred 161 patients with prostate cancer BCR (median prostate-specific antigen value, 1....
71 CitationsSource
#1Quentin Gillebert (UPMC: Pierre-and-Marie-Curie University)H-Index: 2
#2Virginie Huchet (UPMC: Pierre-and-Marie-Curie University)H-Index: 13
Last. Jean-Noël Talbot (UPMC: Pierre-and-Marie-Curie University)H-Index: 32
view all 10 authors...
AIM: To prospectively evaluate the clinical impact and the diagnostic performance of FCH-PET/CT in patients with occult biochemical recurrence of prostate cancer (PCa). MATERIALS AND METHODS: Results of 179 patients (mean PSA = 7.5ng/mL) with negative/inconclusive results of pelvic-MRI and of bone-scintigraphy were analysed. To determine the impact of FCH-PET/CT on diagnostic thinking and on patient management, the referring physicians prospectively filled-in a 1st and 2nd questionnaire related ...
13 CitationsSource
#1Walter ArtibaniH-Index: 62
#1Walter ArtibaniH-Index: 53
Last. Salvatore SiracusanoH-Index: 22
view all 5 authors...
How to manage patients with prostate cancer (PCa) with biochemical recurrence (BCR) following primary curative treatment is a controversial issue. Importantly, this prostate-specific antigen (PSA)-onl
57 CitationsSource
#1Ivar S Jensen (Precision Health Economics)H-Index: 3
#2Philip L. Cyr (Precision Health Economics)H-Index: 5
Last. D GaudenH-Index: 1
view all 3 authors...
1 CitationsSource
#1Thomas A. Hope (UCSF: University of California, San Francisco)H-Index: 39
#2Rahul Aggarwal (UCSF: University of California, San Francisco)H-Index: 26
Last. Peter R. Carroll (UCSF: University of California, San Francisco)H-Index: 141
view all 11 authors...
: The purpose of this prospective study was to estimate the effect of 68Ga-labeled prostate-specific membrane antigen (PSMA)-11 PET on the intended management of patients with biochemically recurrent prostate cancer. Methods: Pre- and postimaging surveys were filled out by the referring providers for patients with biochemical recurrence who were imaged using 68Ga-PSMA-11 PET. The inclusion criterion for this study was a prostate-specific antigen (PSA) doubling time of less than 12 mo after initi...
74 CitationsSource
Cited By21
#1Bital Savir-Baruch (Loyola University Medical Center)H-Index: 13
#2Rudolf A. WernerH-Index: 23
Last. David M. Schuster (Emory University)H-Index: 33
view all 0 authors...
The role of PET imaging with 11C-choline and 18F-fluciclovine in evaluating patients with prostate cancer (PCa) has become more important over the years and has been incorporated into the NCCN guidelines. A new generation of PET radiotracers targeting the prostate-specific membrane antigen (PSMA) is widely used outside the United States to evaluate patients with primary PCa and PCa recurrence. PET imaging influences treatment planning and demonstrates a significantly higher disease detection rat...
#1Samuel J. Galgano (UAB: University of Alabama at Birmingham)H-Index: 7
#2Jonathan McConathy (UAB: University of Alabama at Birmingham)H-Index: 25
#1Eric H. Kim (WashU: Washington University in St. Louis)H-Index: 16
#2Barry A. Siegel (WashU: Washington University in St. Louis)H-Index: 103
Last. Gerald L. Andriole (WashU: Washington University in St. Louis)H-Index: 97
view all 4 authors...
Abstract Introduction Despite improvements in overall survival, biochemical recurrence of prostate cancer, characterized by rising prostate-specific antigen (PSA) levels after curative intent primary therapy, remains common. With the advent of highly sensitive molecular imaging, men with limited metastatic disease burden, or oligometastatic prostate cancer, are increasingly being identified. The LOCATE trial (NCT02680041) assessed the impact of positron emission tomography (PET) with 18F-flucicl...
1 CitationsSource
#1Ashesh B. Jani (Emory University)H-Index: 35
#2Eduard Schreibmann (Emory University)H-Index: 28
Last. David M. Schuster (Emory University)H-Index: 33
view all 19 authors...
Summary Background Molecular imaging is increasingly used to guide treatment decisions and planning in prostate cancer. We aimed to evaluate the role of 18F-fluciclovine-PET/CT in improving cancer control compared with conventional imaging (bone scan and either CT or MRI) alone for salvage postprostatectomy radiotherapy. Methods In EMPIRE-1, a single-centre, open-label, phase 2/3 randomised controlled trial, patients with prostate cancer with detectable PSA after prostatectomy and negative conve...
6 CitationsSource
#1Soroush Rais-Bahrami (UAB: University of Alabama at Birmingham)H-Index: 48
#2Jason A. Efstathiou (Harvard University)H-Index: 55
Last. Andrew Scarsbrook (University of Leeds)H-Index: 9
view all 7 authors...
BACKGROUND A systematic literature review of the performance of 18Fluorine-fluciclovine PET/CT for imaging of men with recurrent prostate cancer was performed. METHODS Scientific literature databases (MEDLINE, ScienceDirect and Cochrane Libraries) were searched systematically during Oct 2020 using PRISMA criteria. No limit was put on the date of publication. Prospective studies reporting a patient-level 18F-fluciclovine detection rate (DR) from ≥25 patients with recurrent prostate cancer were so...
1 CitationsSource
#1Sophia C. Kamran (Harvard University)H-Index: 16
#2Jason A. Efstathiou (Harvard University)H-Index: 55
Radiation therapy plays a crucial role for the management of genitourinary malignancies, with technological advancements that have led to improvements in outcomes and decrease in treatment toxicities. However, better risk-stratification and identification of patients for appropriate treatments is necessary. Recent advancements in imaging and novel genomic techniques can provide additional individualized tumor and patient information to further inform and guide treatment decisions for genitourina...
1 CitationsSource
#1Václav PtáčníkH-Index: 3
#2David ZogalaH-Index: 4
Karcinom prostaty je nejcastějsim malignim onemocněnim mužů. I po radikalni lecbě dochazi u významne casti pacientů k relapsu onemocněni, to je provazeno stoupajici hladinou PSA. Pro optimalni nastaveni terapie je třeba relaps lokalizovat. Fluciklovin je radiofarmakem pro zobrazovani pomoci PET. Vykazuje zvýsenou miru vychytavani v buňkach karcinomu prostaty, proto PET/CT s fluciklovinem představuje senzitivni metodu lokalizace rekurence karcinomu prostaty. Clanek shrnuje poznatky o použiti PET/...
#1Ali Baiomy (University of Texas MD Anderson Cancer Center)H-Index: 2
#2Lucia MartiniovaH-Index: 1
Last. Gregory RavizziniH-Index: 10
view all 5 authors...
ABSTRACT A 66-year-old man with prostate adenocarcinoma status post radical retropubic prostatectomy and bilateral pelvic lymph node dissection, followed by salvage external beam radiation therapy to the prostate bed 1 year after surgery. Over the course of 17 years, the patient underwent multiple lines of systemic treatment for recurrent disease. He was referred for restaging 18F-fluciclovine PET/CT due to rising serum prostate-specific antigen levels. Contrast-enhanced 18F-fluciclovine PET/CT ...